The intention of this current study is to intensify the bioavailability of drugs which have lower bioavailability (<20 %) like Lovastatin in the form of NLC carrier and also to optimize the formulation to select perfect variables for the formulation. The Nanostructures lipid carrier was formulated using Hot Homogenization technique with some optimization by utilizing 23 factorial design with the heal of response like in-vitro drug release, % Entrapment Efϑiciency (EE%), % drug Content (%DC), Zeta potential (Zp), Polydispersity Index (PI) and Particle Size (PS) for 12 hours. The kinetic studies of in-vitro drug release was performed and the parameters of the drug in different kinetic models like higuchi kinetic, zero order, ϑirst order, peppas models were evaluated. Invitro release kinetics studies show that optimized formulation NLC (N3) obeys Super Case II kinetics transport mechanism i.e., release of drug through reduction of attractive forces between Lipid chains and Zero order release kinetics for controlled drug delivery. Hence Nanostructure lipid carrier shows a good control and predetermined rate of drug release of Lovastatin. From the obtained outcome, N3 formulation was concluded as an optimized formulation with selected formulation variables like Solid Lipid: Liquid Lipid ratio (6:4), Span 80 as Surfactant (1%) and process variables like homogenization Speed as 5000 Rotations per minute for 15 mins.><20 %) like Lovastatin in the form of NLC carrier and also to optimize the formulation to select perfect variables for the formulation. The Nanostructures lipid carrier was formulated using Hot Homogenization technique with some optimization by utilizing 23 factorial design with the heal of response like in-vitro drug release, % Entrapment Efficiency (EE%), % drug Content (%DC), Zeta potential (Zp), Polydispersity Index (PI) and Particle Size (PS) for 12 hours. The kinetic studies of in-vitro drug release was performed and the parameters of the drug in different kinetic models like higuchi kinetic, zero order, first order, peppas models were evaluated. Invitro release kinetics studies show that optimized formulation NLC (N3) obeys Super Case II kinetics transport mechanism i.e., release of drug through reduction of attractive forces between Lipid chains and Zero order release kinetics for controlled drug delivery. Hence Nanostructure lipid carrier shows a good control and predetermined rate of drug release of Lovastatin. From the obtained outcome, N3 formulation was concluded as an optimized formulation with selected formulation variables like Solid Lipid: Liquid Lipid ratio (6:4), Span 80 as Surfactant (1%) and process variables like homogenization Speed as 5000 Rotations per minute for 15 mins.
FORMULATION AND IN-VITRO EVALUATION OF THEOPHYLLINE HYDROCHLORIDE EFFERVESCENT FLOATING TABLETS: EFFECT OF POLYMER CONCENTRATION ON TABLET BUOYANCY
